黄葵胶囊联合缬沙坦治疗糖尿病肾病效果研究

目的探究糖尿病肾病患者接受黄葵胶囊联合缬沙坦治疗的临床应用效果。方法2016年1月—2019年12月期间,从该科接收的糖尿病肾病患者中,选出102例为研究对象,并将其随机分为两组,接受缬沙坦单独治疗的51例患者为对照组,接受黄葵胶囊联合缬沙坦治疗的51例患者为观察组,对比患者血糖与肾功能指标差异。结果治疗后,观察组FPG(7.52±1.23)mmol/L、2 hPG(7.71±0.94)mmol/L、HbA1c(5.24±0.63)%与对照组相比差异有统计学意义(t=3.831、6.687、4.040,P<0.05);观察组经治疗,患者腰膝酸软(1.36±0.69)分、浮肿(1.15±0.76)分、疲倦乏力(1.04±0.41)分、肢体麻木(0.56±0.02)分,与对照组相比明显更低,差异有统计学意义(P<0.05);观察组Scr(97.25±20.24)μmol/L、BUN(5.67±1.23)mmol/L与对照组相比差异无统计学意义(t=0.332、0.245,P>0.05);观察组治疗后UAER(88.49±16.78)μg/min低于对照组,差异有统计学意义(t=6.440,P<0.05)。观察组发生口干、头晕及胃肠不适患者共5例,其发生率为9.80%,低于对照组的25.49%,差异有统计学意义(χ²=4.318,P<0.05)。结论糖尿病肾病患者接受黄葵胶囊联合缬沙坦治疗,对患者血糖水平、临床症状与肾功能改善效果显著,疗效明显强于缬沙坦单独治疗,推荐临床应用。

Study on the Effect of Huangkui Capsule Combined with Valsartan in the Treatment of Diabetic Nephropathy

Objective To explore the clinical application effect of Huangkui capsule combined with valsartan in patients with diabetic nephropathy.Methods From January 2016 to December 2019,selected 102 patients with diabetic nephropathy admitted to the department as research subjects,and randomly divided them into two groups.51 patients who received valsartan alone treatment as the control group,51 patients who received Huangkui capsule combined with valsartan as the observation group.The differences in blood glucose and renal function indexes of the patients were compared.Results After treatment,FPG(7.52±1.23)mmol/L,2 hPG(7.71±0.94)mmol/L and HbA1c(5.24±0.63)%in the observation group were significantly different from those in the control group(t=3.831,6.687,4.040,P<0.05).After treatment,the patients in the observation group had(1.36±0.69)points of lumbar and knee pain,(1.15±0.76)points of edema,(1.04±0.41)points of fatigue and(0.56±0.02)points of limb numbness,which were significantly lower than those in the control group,the difference was statistically significant(P<0.05);Scr(97.25±20.24)μmol/L,BUN(5.67±1.23)mmol/L in the observation group were not significantly different from those in the control group(t=0.332,0.245,P>0.05).After treatment,the UAER in the observation group was(88.49±16.78)μg/min,which was lower than that in the control group(t=6.440,P<0.05).There were 5 cases of dry mouth,dizziness and gastrointestinal discomfort in the observation group,and the incidence was 9.80%,which was lower than 25.49%in the control group.The difference was statistically significant(χ²=4.318,P<0.05).Conclusion The treatment of diabetic nephropathy patients with Huangkui capsule combined with valsartan can improve the blood glucose level,clinical symptoms and renal function of the patients.The effect is significantly stronger than that of valsartan alone,and clinical application is recommended.